FDA Clears First CLEC2A CAR T Trial for AML
The FDA has cleared a first-in-human CLEC2A CAR T study at three U.S. centers. Researchers will test whether the target can spare normal blood-forming cells.
Antibody 1 article
Adaptive immune recognition protein provides the clearest boundary for antibody, an antigen-binding immunoglobulin class used in a specific molecular or clinical context. The entity links variable heavy and light chains to complementarity-determining regions, and its relevance becomes clearer through antibody-antigen specificity and immunoglobulin Fc region rather than through broader terminology. Antibody is the broad biomolecule class and should not be treated as a synonym for monoclonal-antibody therapy, antibody fragments or bispecific formats.